Cervical Cancer Google News

FDA accepts sBLA, grants priority review for Genentech's cervical cancer ... - Pharmaceutical Business Review

July 16, 2014 - 7:31am

FDA accepts sBLA, grants priority review for Genentech's cervical cancer ...
Pharmaceutical Business Review
The US Food and Drug Administration (FDA) has accepted Genentech's supplemental Biologics License Application (sBLA) and granted priority review for Avastin (bevacizumab) plus chemotherapy to treat women with persistent, recurrent or metastatic ...

Categories: Cervical Cancer News

FDA accepts sBLA, grants priority review for Genentech's cervical cancer ... - Pharmaceutical Business Review

July 16, 2014 - 7:31am

FDA accepts sBLA, grants priority review for Genentech's cervical cancer ...
Pharmaceutical Business Review
The US Food and Drug Administration (FDA) has accepted Genentech's supplemental Biologics License Application (sBLA) and granted priority review for Avastin (bevacizumab) plus chemotherapy to treat women with persistent, recurrent or metastatic ...

Categories: Cervical Cancer News

Priority review for Roche's Avastin in cervical cancer - PMLiVE

July 16, 2014 - 6:58am

Priority review for Roche's Avastin in cervical cancer
PMLiVE
Roche Avastin bevacizumab cancer Roche's Avastin is to undergo an expedited review process in the US for its use in advanced cervical cancer. The FDA granted priority review status to the oncology drug for use in combination with chemotherapy for the ...

Categories: Cervical Cancer News

Roche Group's Avastin for cervical cancer given priority review status by FDA - Tech Times

July 16, 2014 - 6:32am

Tech Times

Roche Group's Avastin for cervical cancer given priority review status by FDA
Tech Times
"This regulatory application for Avastin is important because chemotherapy is the only approved treatment for women with metastatic, recurrent or persistent cervical cancer. Treatment with Avastin plus chemotherapy may help women with these conditions ...

Categories: Cervical Cancer News

US priority review for Avastin in metastatic cervical cancer - PharmaTimes

July 16, 2014 - 5:35am

US priority review for Avastin in metastatic cervical cancer
PharmaTimes
Regulators in the USA have granted a priority review to Roche's blockbuster Avastin in another indication, this time for cervical cancer. Specifically, the US Food and Drug Administration has accepted the company's supplemental Biologics License ...

Categories: Cervical Cancer News

NBCCEDP program markedly reduces death, illness from cervical cancer - News-Medical.net

July 16, 2014 - 1:10am

NBCCEDP program markedly reduces death, illness from cervical cancer
News-Medical.net
A 23-year old federal program for the early detection and treatment of cervical cancer markedly reduces illness and death among underserved, low-income women, yet its impact has been reduced by the fact that it has reached only 10 percent of the ...

and more »
Categories: Cervical Cancer News

FDA Grants Priority Review to Bevacizumab in Advanced Cervical Cancer - OncLive

July 15, 2014 - 5:37pm

FDA Grants Priority Review to Bevacizumab in Advanced Cervical Cancer
OncLive
The FDA has assigned a priority review designation to bevacizumab (Avastin) plus chemotherapy as a treatment for patients with persistent, recurrent, or metastatic cervical cancer. As part of this program, the agency plans to take action on the drug's ...

Categories: Cervical Cancer News

Roche seeks Avastin cervical-cancer indication - Medical Marketing and Media

July 15, 2014 - 4:37pm

Medical Marketing and Media

Roche seeks Avastin cervical-cancer indication
Medical Marketing and Media
Roche scored the FDA's Priority Review label for its billion-dollar drug Avastin for use among patients with persistent, recurrent or metastatic cervical cancer, when paired with chemotherapy. The Priority Review means the supplemental Biologics ...

Categories: Cervical Cancer News

Genentech aims to extend Avastin to cervical cancer - San Francisco Business Times (blog)

July 15, 2014 - 4:26pm

Genentech aims to extend Avastin to cervical cancer
San Francisco Business Times (blog)
South San Francisco-based Genentech, the U.S. biotech unit of Swiss drug maker Roche, said the Food and Drug Administration granted priority review to Avastin plus chemotherapy to treat women with persistent, recurring or metastatic cervical cancer.

Categories: Cervical Cancer News

FDA grants priority review to Avastin for advanced cervical cancer - Healio

July 15, 2014 - 4:17pm

FDA grants priority review to Avastin for advanced cervical cancer
Healio
The FDA has granted priority review to bevacizumab plus chemotherapy for the treatment of women with persistent, recurrent or metastatic cervical cancer, according to a press release issued by the drug's manufacturer. The FDA based its decision in part ...

Categories: Cervical Cancer News

Cervical Cancer Prevention Program Saves Lives - Newswise (press release)

July 15, 2014 - 3:53pm

Cervical Cancer Prevention Program Saves Lives
Newswise (press release)
Newswise — A 23-year old federal program for the early detection and treatment of cervical cancer markedly reduces illness and death among underserved, low-income women, yet its impact has been reduced by the fact that it has reached only 10 percent ...

and more »
Categories: Cervical Cancer News

Avastin Gets Priority Review for Certain Types of Cervical Cancer - Drug Discovery & Development

July 15, 2014 - 3:37pm

Drug Discovery & Development

Avastin Gets Priority Review for Certain Types of Cervical Cancer
Drug Discovery & Development
“This regulatory application for Avastin is important because chemotherapy is the only approved treatment for women with metastatic, recurrent or persistent cervical cancer,” said Sandra Horning, chief medical officer and head of Global Product ...

Categories: Cervical Cancer News

Cervical Cancer Prevention Program Saves Lives - Health Behavior News Service

July 15, 2014 - 12:22pm

Health Behavior News Service

Cervical Cancer Prevention Program Saves Lives
Health Behavior News Service
A 23-year old federal program for the early detection and treatment of cervical cancer markedly reduces illness and death among underserved, low-income women, yet its impact has been reduced by the fact that it has reached only 10 percent of the ...

Categories: Cervical Cancer News

Genital Warts Increase Risk of Cervical and Uterine Cancer; CBCD Reviews the ... - PRunderground

July 15, 2014 - 11:15am

Genital Warts Increase Risk of Cervical and Uterine Cancer; CBCD Reviews the ...
PRunderground
“While cervical cancer is the most common type of cancer associated with HPV, anal cancer, oral cancer, vulvar cancer and cancer of the penis may also be caused by HPV.” (1) The American Association for Cancer research says that “The risk for ...

and more »
Categories: Cervical Cancer News

Priority Review, sBLA Granted for Cervical Cancer Tx - Monthly Prescribing Reference

July 15, 2014 - 10:45am

Priority Review, sBLA Granted for Cervical Cancer Tx
Monthly Prescribing Reference
GOG-0240 assessed the efficacy and safety profile of Avastin plus chemotherapy (paclitaxel and cisplatin or paclitaxel and topotecan) in women with persistent, recurrent, or metastatic cervical cancer. The study data included 452 women and met its ...

Categories: Cervical Cancer News

FDA Gives Roche Priority Review For Cervical Cancer Treatment - Bidness Etc

July 15, 2014 - 9:33am

Bidness Etc

FDA Gives Roche Priority Review For Cervical Cancer Treatment
Bidness Etc
Genentech, a member of Roche Holding AG (RHHBY), was granted a priority review by the Food and Drug Administration (FDA) for its Avastin-plus-chemotherapy treatment for cervical cancer. The FDA approval is based on data from the Phase III GOG-0240 ...

Categories: Cervical Cancer News

FDA Grants Roche's Avastin Priority Review for Certain Types of Cervical Cancer - Pharmaceutical Processing

July 15, 2014 - 8:39am

FDA Grants Roche's Avastin Priority Review for Certain Types of Cervical Cancer
Pharmaceutical Processing
“This regulatory application for Avastin is important because chemotherapy is the only approved treatment for women with metastatic, recurrent or persistent cervical cancer,” said Sandra Horning, M.D., chief medical officer and head of Global Product ...

Categories: Cervical Cancer News

MOHSW Trains Health Workers On Cervical Cancer Screening, Management - AllAfrica.com

July 15, 2014 - 7:34am

MOHSW Trains Health Workers On Cervical Cancer Screening, Management
AllAfrica.com
A two-day training of health workers on cervical cancer screening and management organised by the Ministry of Health Friday ended at the SOS Children's village conference hall in Bakoteh. Sponsored by WHO and the UNFPA, the health workers were ...

Categories: Cervical Cancer News

Avastin + chemo gets priority review for cervical cancer (RHHBY) - Seeking Alpha

July 15, 2014 - 7:00am

Avastin + chemo gets priority review for cervical cancer (RHHBY)
Seeking Alpha
The FDA designates Genentech's (RHHBY +1.1%) sBLA for Avastin (bevacizumab) plus chemotherapy as a treatment for persistent, recurrent or metastatic cervical cancer for priority review. The agency's elevated review process is granted to medicines it ...

Categories: Cervical Cancer News

Roche says wins priority review for Avastin in cervical cancer - Chicago Tribune (blog)

July 15, 2014 - 6:31am

Roche says wins priority review for Avastin in cervical cancer
Chicago Tribune (blog)
An approval by the U.S. Food and Drug Administration for treating advanced cervical cancer would open another large market for the medicine in patients for whom chemotherapy has been largely ineffective. About 4,000 women in the United States and ...

Categories: Cervical Cancer News